# DATA SHARING AGREEMENT

(herein "Agreement")

BETWEEN:	[ORGANIZATION] a corporation under the laws of [JURISDICTION] having its principal place of business at [ADDRESS] (herein "Provider Institution")
AND:	Prof. [NAME OF SCIENTIST] (herein "Provider Scientist")
	(Provider Institution and Provider Scientist are collectively referred to as " <b>Provider</b> ")
AND:	The Royal Institution for the Advancement of Learning/McGill University having a principal place of business at 845 Sherbrooke Street West, James Administration Building, Montréal, Québec, H3A OG4 (hereinafter referred to as " <b>Recipient Institution</b> ") on behalf of COVID-19 Immunity Task Force (herein " <b>CITF</b> ") Secretariat, hosted at McGill University
	Dr. David Buckeridge (herein "Recipient Scientist")
AND:	(Recipient Institution and Recipient Scientist are collectively referred to as " <b>Recipient</b> ")
	(Provider and Recipient are hereinafter referred to individually each as a " <b>Party</b> " and collectively as the " <b>Parties</b> ")

**WHEREAS** Recipient was provided with funding from the Government of Canada through a Contribution Agreement signed on May 29, 2020, to support the activities of the CITF to measure the scope of coronavirus infection in Canada and rapidly provide information needed to manage the COVID-19 pandemic;

**WHEREAS** the Provider is the recipient of funds from [the Government of Canada through the Public Health Agency of Canada (PHAC)/the Canadian Institutes for Health Research (CIHR)/Other] to carry out the project [NAME OF PROJECT] as described under Appendix 1 (herein "**Research Project**");

**WHEREAS** the Recipient through the CITF Secretariat, is mandated to coordinate multi-site sero-surveys assessing COVID-19 immunity in the Canadian population and to provide regular scientific updates to the Government of Canada on the state of serologic testing and the evolving understanding of immunity related to SARS-CoV-2 (herein "**Study**");

WHEREAS the Study will include the creation of a database where the Data that is shared by Provider with Recipient will be centralized, harmonized, and stored (herein "**CITF Database**) as defined in the Framework to support the Study (herein "**CITF Data**").

**WHEREAS** the CITF Data will be securely made available to third parties through the access framework for further research;

**WHEREAS** Recipient has established the organizational structure, technical elements, and operational policies fundamental to the CITF's mandate as per Appendix 3, the CITF Data Governance Framework (herein "Framework");

**WHEREAS** the Provider is willing to provide Recipient for use in the Study certain data arising from the Research Project as per the terms and conditions set out in this Agreement.

**NOW THEREFORE THIS AGREEMENT WITNESSETH** that in consideration of the premises and covenants set out in this Agreement, the Parties agree as follows:

#### 1. DEFINITIONS.

In this Agreement, the following words have the following definitions:

- 1.1. **"Data"** means all personal data (including without limitation medical data and information and other personal health information) and non-personal data and associated metadata that has been collected for the purpose of the Research Project by Provider to Recipient for the purpose of carrying out the Study, as further set out in Appendix 2. The Data will have direct identifiers removed and Provider will code the data where the key for participants identification will only be held by the Provider;
- 1.2. "Controlled Access" means Data that will be held securely and access will only be made available through CITF-approved requests that are in compliance with Framework;
- 1.3. "Open Access" means Data that will be made freely available, to be used and republished;
- 1.4. "Effective Date" means the date upon which the Agreement becomes effective and corresponds to date of the last signature to the Agreement;

#### 2. PROVIDER'S OBLIGATIONS

- 2.1. Provider shall provide the Data to Recipient to be centralized, harmonized and stored in the CITF Database as further set out in the Framework. The Data shall be provided in accordance with the milestones/deliverables set out in Appendix 1.
- 2.2. Provider represents and warrants having the necessary authority to share the Data with Recipient in accordance with this Agreement and, without limiting the generality of the foregoing, the Framework. Provider will prepare and furnish Data in accordance with all applicable laws, regulations, guidelines and policies, including, but not limited to laws regarding the privacy or protection of personal or medical information and the Quebec Act Respecting Access to Documents Held by Public Bodies and the Protection of Personal Information ("Applicable Law"). Provider has obtained all appropriate participant consents including as described in the Framework. Data will not be collected and/or transferred until Provider's research ethics board ("REB") and, if applicable Provider's third-party REB and Recipient's REB, have: a) approved the

Research Project protocol, including the transfer of the Data to Recipient for inclusion in the CITF Database; and b) approved the Research Project informed consent forms or waived the requirement to obtain consent.

2.3. Upon transfer of the Data from Provider to Recipient in accordance with the Framework, the Provider will have to acknowledge and agree to the terms of a data sharing agreement.

#### 3. **RECIPIENT'S OBLIGATIONS**

- 3.1. Recipient shall only use the Data in compliance with this Agreement and the Framework. Without limiting the generality of the foregoing, Recipient shall not use the Data to attempt to identify or make contact with any of Provider's research participants.
- 3.2. Recipient, will safeguard the Data in a secure infrastructure physically Gilocated in Canada, or in another secured database in compliance with the Framework and Applicable Law. If CITF were to become inactive, Recipient will be able to transfer the Data to a third party organization for its long-term safekeeping and preservation. This transfer will be subject to a new agreement between Recipient and such third-party organization in compliance with the Framework and Applicable Law.
- 3.3. Recipient will use reasonable efforts to maintain the confidentiality of the Data and to prevent any unauthorized access, reproduction, disclosure and/or use of the Data. Notwithstanding the above, Provider acknowledges and agrees that the Data and CITF Data may be accessed by third parties for defined uses consistent with the mandate of CITF as more fully described in the Framework, for example, through Controlled Access, and/or Open Access. In addition, Recipient may transfer the Data:

(i) to regulatory authorities, provided that the Recipient gives prior written notice of such intended disclosure to Provider;

(ii) in order to comply with Applicable Law or judicial process, or with a court or regulatory order, provided that Recipient gives prior written notice of such intended disclosure to Provider and takes all lawful actions that are reasonable in the circumstances to minimize the extent of such disclosure and obtain confidential treatment for such disclosure.

3.4. In the event of an actual or reasonably suspected breach of confidentiality, or unauthorized disclosure by mistake or otherwise of Data, Recipient shall promptly give written notice of such to the Provider and shall work with Provider to prevent further disclosure and limit potential damages caused by such disclosure.

#### 4. DISCLAIMER AND LIABILITY

- 4.1. Except as expressly set out herein, neither Party makes any representations, warranties, conditions or liabilities expressed or implied herewith in relation to any matter hereunder.
- 4.2. Neither Party shall be liable to the other for indirect or consequential damages.

#### 5. INTELLECTUAL PROPERTY AND RELATED RIGHTS

5.1. The Provider hereby agrees that the Data be treated in accordance with the intellectual property and related rights as described in the Framework. The Provider hereby waives any right to claim any

interest in any intellectual property rights that may arise out of use of the Data by third parties pursuant to the Framework.

#### 6. PUBLICATION.

6.1. Any communication with the CITF Secretariat will be as per Section 16, Notices. Provider Institution and Provider Scientist acknowledge that CITF Secretariat may publicize the projects and investigators it supports through the internet, social media, press releases, printed materials released to the public, public reports, speeches, newsletters, and other media, as well as in marketing and promotional materials, in accordance with applicable laws.

6.2. The Provider Scientist agrees to submit, in a timely manner, such information, written material, images, photographs, video, or other content related to the Research Project (the "**Publicity Content**") as may be reasonably requested by the CITF Secretariat to contribute to these publicity efforts. The Provider Scientist consents to the publication of her/his name, as well as names of all co-applicants and collaborators, the title of the Research Project, and the amount of the award, and event photos in association with this award (e.g. on the CITF website).

6.3. The Provider Scientist acknowledges and agrees that (i) all information in submitted Publicity Content shall be accurate, (ii) the Provider Scientist shall notify the CITF Secretariat of any subsequent change that renders such information materially inaccurate, (iii) the Provider Scientist shall notify the CITF Secretariat in writing of any credits that are required to be associated with the Publicity Content, and (iv) any persons that are individually identifiable in the submitted Publicity Content (or, for persons under the legal age of consent in the applicable jurisdiction, their parents or guardians) shall have consented to the uses contemplated herein. Recipient acknowledges that Provider Scientist and/or Provider Institution may also publicize the Research Project on its website, intranet and/or internal newsletters, in accordance with Provider Institution's internal policies and procedures and applicable laws.

6.4. The Provider Scientist shall have the right to publish the results of, or accounts of, the Project. While there is no mandatory requirement for notification of publication or review of publication from funded studies by the CITF to the CITF Secretariat, bi-directional communication is strongly encouraged to support common interpretation of the Data and coordinated public health messaging. More specifically:

- 6.4.1. The CITF Secretariat will establish a process for providing feedback on manuscripts. Provider Scientist can notify the CITF Secretariat of intent to publish and the CITF Secretariat will endeavor to review the manuscript and highlight any issues that may benefit from discussion.
- 6.4.2.The CITF Secretariat will also endeavor to engage with Provider Scientist around analyses to synthesize core data elements drawn from multiple studies that have data.
- 6.4.3.Researchers accessing centralized core data elements from the CITF Data Access Committee (DAC) will not be required to notify the CITF regarding publications.

6.5. The following acknowledgment shall be included in any publications that result from or in relation to the Project that received funding from the CITF "*This project was supported by funding from the Government of Canada, through the COVID-19 Immunity Task Force.*/ *Ce projet a été soutenu par un financement du Gouvernement du Canada, par le biais du Secrétariat du groupe de travail sur l'immunité COVID-19*" unless the McGill CITF Secretariat has advised otherwise. The Parties agree that any scientific publication made pursuant to this Agreement shall be made in accordance with the custom of scientific research and shall acknowledge the contribution of the Parties' scientists, as appropriate. Specifically for third-party users that are not funded studies by the CITF and have requested and received approval to access centralized core data elements from the DAC, these third-party users will attribute the CITF in

publications where the attribution could be a link to a dynamic list of studies contributing data to the CITF, or by citing a central marker paper describing the work and authored by CITF Secretariat individuals that includes Principal Investigators from contributing studies.

#### 7. TERM.

7.1. The term of this Agreement shall be as per Appendix 1 and provisions for survival will be as per Section 12.

7.2. Provider may request withdrawal of the Data in the following manner:

- 7.2.1. there is a research participant or sample donor withdrawal request for their own personal data;
- 7.2.2. there is a change in the data custodian and the data governance conditions established in Framework;
- 7.2.3. CITF ceases to exist;

Notwithstanding the above, Data that has already been shared with third parties external to the CITF will not be withdrawn from such third parties; and Data that is being used by a research study, the destruction of which would compromise the integrity of that research study, will not be destroyed from the CITF Database until after the research study is completed, to preserve the scientific integrity of the concerned research.

8. NOTICES. All notices: (a) shall be in writing and shall be deemed to have been given on the date they are: (i) delivered by hand; (ii) received from any reputable delivery service that provides tracking and written verification of delivery; or (iii) transmitted by e-mail, all if given on a business day prior to 5:00 pm failing which they shall be deemed to be given, delivered or made the next business day; (b) shall be given at the following addresses or at such other address as may be indicated by one party to the other by notice as aforesaid:

*If to CITF Secretariat:* 

Olivia Oxlade Associate Scientific Director (Management) Email: <u>olivia.oxlade@mcgill.ca</u>

With a copy to McGill:

McGill University Office of Sponsored Research James Administration Building 845 Sherbrooke W., 2nd floor Montreal Quebec, H3A 0G4 Attn: Carole Goutorbe Associate Director Awards Management Email: <u>carole.goutorbe@mcgill.ca</u>

*If to Provider Institution:* To be completed

with a copy to Provider Scientist: To be completed

**9. USE OF NAME.** Provider shall not use Recipient's name or trademark or any adaptation thereof without the prior written consent of its duly authorized representative.

**10.** WAIVER OF RIGHTS. No waiver or failure by the Parties to enforce their right or insist on strict performance of this Agreement shall be deemed to prevent the Parties from subsequently enforcing their rights or insist on strict performance under the Agreement. No waiver or failure to strictly enforce rights shall affect the validity of this Agreement.

**11. SEVERABILITY**. The invalidity or unenforceability of any provision of this Agreement shall not affect the validity or enforceability of the Agreement itself or any of its provisions.

**12. SURVIVAL.** The provisions of sections 3, 4, 5, 6, 7.2 and 9, shall survive the termination of this Agreement with section 3 surviving termination of this Agreement until CITF ceases to exist.

**13. ASSIGNMENT.** Neither Party shall have the right to assign this Agreement without the written consent of the other Party. Such consent shall not be unreasonably withheld.

**14. HEADINGS.** The headings contained in this Agreement are for convenience and reference only and shall not define or limit the scope, or affect the interpretation of, its provisions.

**15. AMENDMENTS.** Any modification to this Agreement shall be agreed to in writing and approved by an authorized representative of the Parties.

**16. COUNTERPARTS.** This Agreement may be executed in one or more counterparts, each of which together shall constitute one and the same Agreement. For purposes of executing this Agreement, a facsimile (including a PDF image delivered via email) copy of this Agreement, including the signature pages, will be deemed an original.

**17.** LANGUAGE. Les Parties ont requis que cette entente soit rédigée en anglais. The Parties have requested that this Agreement be drafted in English.

**18. GOVERNING LAW.** This Agreement shall be governed by the laws of Québec, and Canadian laws applicable therein without regard to their provisions on conflict of Law.

#### [The remainder of the page is blank. Signature page follows.]

**IN WITNESS WHEREOF** Provider and Recipient have caused this Agreement to be executed in duplicate by their respective duly authorized representatives.

The Royal Institution for the Advancement of Learning/McGill University

By its authorized signatory:

[Organization]

By its authorized signatory:





Name: Carole Goutorbe Title: Associate Director, Office of Sponsored Research Date: Name: [ORGANIZATION SIGNATORY] Title: [TITLE] Date:

#### Acknowledgment

I, Dr. David Buckeridge, Scientific Lead Data Management, CITF Secretariat, having read and understood this Agreement, hereby agree to act in accordance with all the terms and conditions herein and further agree to ensure that all Provider participants are informed of their obligations under said terms and conditions. Acknowledgment

I, [SCIENTIST], having read and understood this Agreement, I hereby agree to act in accordance with all the terms and conditions herein and further agree to ensure that all Recipient participants are informed of their obligations under said terms and conditions.

Dr. David Buckeridge Scientific Lead Data Management, CITF Secretariat

[SCIENTIST 1]

### Appendix 1 Description of Research Project

[Please provide a detailed description of the research project: (use additional pages as needed)]

This Appendix must have the following minimal information which is referred to in this Agreement:

- Scope of Work, (the technical and scientific description of the Project);
- Deliverables
- Responsibilities and duties of Scientific Coordinators;
- Time schedule, including any milestones;

## Appendix 2

Description of Core Data Elements and Associated Metadata



### Appendix 2: CITF Core Data Elements, cross-sectional studies, Version 2

CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
-	00	Unique participant's identifier	string	single	Guidelines will be provided	-
DEMOGRAPHIC	01	Date of interview	date	single	"YYYY-MM-DD"	Date of interview
DEMOGRAPHIC	02.a	Age of participant (years)	numerical	single	[0, 120]	What is your age
DEMOGRAPHIC	02.b	Age of participant (months)	numerical	single	[0, 11]	What is your age
DEMOGRAPHIC	02.c	Age of participant PNA				What is your age
DEMOGRAPHIC	03	Sex at birth of participant	categorical	single	{01-MALE, 02-FEMALE, 03-PREFER TO SELF-DESCRIBE, 99-PREFER NOT TO ANSWER}	What was your assigned sex at birth
DEMOGRAPHIC	03.a	Sex at birth self- description	string	single		(specify)
DEMOGRAPHIC	04	Current sex of participant	categorical	single	{01-MALE, 02-FEMALE, 03-PREFER TO SELF-DESCRIBE, 99-PREFER NOT TO ANSWER}	What is your sex now
DEMOGRAPHIC	04.a	Current sex self- description	string	single		(specify)
DEMOGRAPHIC	05	Gender of participant	categorical	single	{01-MAN, 02-WOMAN, "03-NON-BINARY, GENDERQUEER, AGENDER OR A SIMILAR IDENTITY", 04-TWO-SPIRIT, 05-PREFER TO SELF-DESCRIBE, 99-PREFER NOT TO ANSWER}	What is your gender (How do you currently self-identify)
DEMOGRAPHIC	05.a	Gender self- description	string	single		(specify)
DEMOGRAPHIC	06	Indigenous identity of participant	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Are you an Indigenous person originating from North America
DEMOGRAPHIC	07	Indigenous group	categorical	multiple	{01-FIRST NATIONS, 02-INUIT, 03-MÉTIS, 04-NON-STATUS FIRST NATIONS, 05-OTHER INDIGENOUS, 99-PREFER NOT TO ANSWER}	Which of the following groups do you belong to [SELECT ALL THAT APPLY]
DEMOGRAPHIC	07.a	Other indigenous group specification	string	single		(specify)
DEMOGRAPHIC	08	Reserve occupation	categorical	single	{01-YES, 02-NO, 99-PREFER NOT TO ANSWER}	Do you live on reserve
DEMOGRAPHIC	09	Ethnicity of participant	categorical	multiple	{01-WHITE, 02-SOUTH ASIAN, 03-CHINESE, 04-BLACK, 05-FILIPINO, 06-LATIN AMERICAN, 07-ARAB, 08-SOUTHEAST ASIAN, 09-WEST ASIAN, 10-KOREAN, 11-JAPANESE, 12-PREFER TO SELF-DESCRIBE, 99-PREFER NOT TO ANSWER}	How would you describe your ethnicity or race [SELECT ALL THAT APPLY] If you are an Indigenous person and answered YES to question 6, select any other that apply.
DEMOGRAPHIC	09.a	Other ethnicity specification	string	single		(specify)
DEMOGRAPHIC	10	Postal code of participant's address	string	single	"\w\d\w" (three-character pattern: letter-digit-letter)	What are the first three digits of your postal code
DEMOGRAPHIC	10.a	Postal code PNA	categorical	single	99-PREFER NOT TO ANSWER	What are the first three digits of your postal code
DEMOGRAPHIC	11	Level of education of participant	categorical	single	{01-LESS THAN HIGH SCHOOL GRADUATION, 02-HIGH SCHOOL GRADUATION, "03-TRADE CERTIFICATE, VOCATIONAL SCHOOL, OR	What is the highest level of education you have completed



CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
					APPRENTICESHIP TRAINING", "04-NON-UNIVERSITY CERTIFICATE OR	
					DIPLOMA FROM A COMMUNITY COLLEGE, CEGEP", 05-UNIVERSITY	
					BACHELOR'S DEGREE, 06-UNIVERSITY GRADUATE DEGREE (SUCH AS	
					A MASTERS OR DOCTORATE), 99-PREFER NOT TO ANSWER}	
DEMOGRAPHIC	12	Number of residents	numerical	single	[1, 20]	How many people live in your
		in household				household, including yourself
DEMOGRAPHIC	12.a	Number of residents	categorical	single	99-PREFER NOT TO ANSWER	How many people live in your
		in household PNA				household, including yourself
DEMOGRAPHIC	13	Number of bedrooms	numerical	single	[0, 20]	How many bedrooms in your
		in household				household
DEMOGRAPHIC	13.a	Number of bedrooms	categorical	single	99-PREFER NOT TO ANSWER	How many bedrooms in your
		in household PNA				household
DEMOGRAPHIC	14	Number of bathrooms	numerical	single	[0, 20]	How many bathrooms in your
		in household				household
DEMOGRAPHIC	14.a	Number of bathrooms	categorical	single	99-PREFER NOT TO ANSWER	How many bathrooms in your
		in household PNA				household
COVID-19	15	Participant's COVID-	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Do you think you have had COVID-19
		19 self-assessment				
COVID-19	16	Participant's COVID-	categorical	multiple	{01-SYMPTOM REVIEW ONLINE, 02-SYMPTOM PROFILE, "03-	Why do you think you have had COVID-
		19 self-assessment:			NASAL/THROAT TEST RESULT", 04-HEALTH CARE PROVIDER, 05-	19 [SELECT ALL THAT APPLY]
		reason for suspect			CONTACT WITH CASE, 06-OTHER (SPECIFY), 99-PREFER NOT TO	
		COVID			ANSWER}	
COVID-19	16.a	Other reason for	string	single		(specify)
		COVID self-				
		assessment				
		specification				
COVID-19	17	Participant's	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Were you hospitalized due to COVID-19
		hospitalization due to				
		COVID-19				
COVID-19	18	Participant's previous	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Have you ever been tested for an active
		COVID-19 testing				COVID-19 infection (using
						nasopharyngeal, throat swab, saliva or
						gargle test)
COVID-19	19	Participant's number	numerical	single	[1, 1000]	If Yes, how many times have you been
		of previous COVID-19				tested
		tests				
COVID-19	19.a	Participant's number	categorical	single	99-PREFER NOT TO ANSWER	If Yes, how many times have you been
		of previous COVID-19				tested
		tests PNA				
COVID-19	20.1					Answer the following questions about
						the first test
						(if applicable):
COVID-19	20.1.a	Date of 1st COVID-19	date	single	"YYY-MM"	What was the date of the first test
		test		_		



COVID-19 IMMUNITY TASK FORCE GROUPE DE TRAVAIL SUR L'IMMUNITÉ FACE À LA COVID-19

CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
COVID-19	20.1.b	Result of 1st COVID test	categorical	single	{01-POSITIVE, 00-NEGATIVE, 98-UNKNOWN}	What was the result of the first test
COVID-19	20.1.c	Participant's COVID- 19 symptom status (1st test)	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW}	Did you have any symptoms of COVID when you had this test
COVID-19	20.1.d	Participant's COVID- 19 symptoms (1st test)	categorical	multiple	{01-COUGH, 02-FEVER, 03-SHORTNESS OF BREATH, 04-SORE MUSCLES, 05-HEADACHE, 06-SORE THROAT, 07-DIARRHEA, 08- DECREASED SENSE OF SMELL OR TASTE, 09-OTHER (SPECIFY), 99- PREFER NOT TO ANSWER}	(specify)
COVID-19	20.1.e	Participant's COVID- 19 other symptoms (1st test)	string	single		If yes, what symptoms did you have: OTHER [SPECIFY]
COVID-19	20.2					Answer the following questions about the second test (if applicable):
COVID-19	20.2.a	Date of 2nd COVID-19 test	date	single	"YYYY-MM"	What was the date of the second test? [IF APPLICABLE]
COVID-19	20.2.b	Result of 2nd COVID test	categorical	single	{01-POSITIVE, 00-NEGATIVE, 98-UNKNOWN}	What was the result of the second test? [IF APPLICABLE]
COVID-19	20.2.c	Participant's COVID- 19 symptom status (1st test)	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW}	Did you have any symptoms of COVID when you had this test
COVID-19	20.2.d	Participant's COVID- 19 symptoms (1st test)	categorical	multiple	{01-COUGH, 02-FEVER, 03-SHORTNESS OF BREATH, 04-SORE MUSCLES, 05-HEADACHE, 06-SORE THROAT, 07-DIARRHEA, 08- DECREASED SENSE OF SMELL OR TASTE, 09-OTHER (SPECIFY), 99- PREFER NOT TO ANSWER}	If yes, what symptoms did you have [SELECT ALL THAT APPLY]
COVID-19	20.2.e	Participant's COVID- 19 other symptoms (1st test)	string	single		(specify)
COVID-19	20.3					Answer the following questions about the third test (if applicable):
COVID-19	20.3.a	Date of 3rd COVID-19 test	date	single	"YYY-MM"	What was the date of the third test? [IF APPLICABLE]
COVID-19	20.3.b	Result of 3rd COVID test	categorical	single	{01-POSITIVE, 00-NEGATIVE, 98-UNKNOWN}	What was the result of the third test? [IF APPLICABLE]
COVID-19	20.3.c	Participant's COVID- 19 symptom status (1st test)	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW}	Did you have any symptoms of COVID when you had this test
COVID-19	20.3.d	Participant's COVID- 19 symptoms (1st test)	categorical	multiple	{01-COUGH, 02-FEVER, 03-SHORTNESS OF BREATH, 04-SORE MUSCLES, 05-HEADACHE, 06-SORE THROAT, 07-DIARRHEA, 08- DECREASED SENSE OF SMELL OR TASTE, 09-OTHER (SPECIFY), 99- PREFER NOT TO ANSWER}	If yes, what symptoms did you have [SELECT ALL THAT APPLY]



COVID-19 IMMUNITY TASK FORCE GROUPE DE TRAVAIL SUR L'IMMUNITÉ FACE À LA COVID-19

CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
COVID-19	20.3.e	Participant's COVID- 19 other symptoms (1st test)	string	single		(specify)
COVID-19	20.4.a	Participant's other test positive status	categorical	single	{NO, YES}	Have you tested positive for COVID-19 (using nasopharyngeal, throat swab, saliva or gargle test) on a test that wasn't included in the questions above (that is, on the 4th or later test)
COVID-19	20.4.b	Other positive test date	date	single	"YYY-MM"	If yes, what was the date the first time you tested positive?
EXPOSURE	22	Participant's travel history outside province before January 2020	categorical	single	{01-YES, 02-NO, 99-PREFER NOT TO ANSWER}	Have you travelled outside of your home province since January 2020
EXPOSURE	22.a	Participant's travel history outside province before symptoms	categorical	single	{01-YES, 02-NO, 99-PREFER NOT TO ANSWER}	If you think you have had COVID, did you travel in the 6 months before your symptoms began?
EXPOSURE	23	Participant's travel history by geographic location	categorical	multiple	Provinces: {02-BRITISH COLUMBIA, 01-ALBERTA, 12- SASKATCHEWAN, 03-MANITOBA, 09-ONTARIO, 11-QUEBEC, 04- NEW BRUNSWICK, 07-NOVA SCOTIA, 10-PRINCE EDWARD ISLAND, 05-NEWFOUNDLAND AND LABRADOR, 08-NUNAVUT, 06- NORTHWEST TERRITORIES, 13-YUKON}	What province or country did you travel to [SELECT ALL THAT APPLY]
EXPOSURE	23.a	Participant's travel history by geographic location	categorical	multiple	Countries: ISO 3166-1 (https://www.iso.org/obp/ui/#search/code/)	What province or country did you travel to [LIST COUNTRIES YOU TRAVELLED TO (separated by a comma)]
EXPOSURE	24.a	Participant's work history	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Do you do either paid or unpaid work in an environment where you work in close proximity to other people
EXPOSURE	24.b	Participant's occupation	categorical	multiple	{01-HOSPITAL OR HEALTH CARE FACILITY WORKER, "02-FIRST RESPONDER (PARAMEDIC, FIREFIGHTER, POLICE OFFICER)", 03- CHILDCARE WORKER, 04-CORRECTIONAL OFFICER, 05-TEACHER OR OTHER SCHOOL STAFF, 06-TRANSIT DRIVER, 07-FOOD SERVICE INDUSTRY, 08-GROCERY STORE, 09-PHARMACY, 10-HAIRDRESSER OR BARBER, 11-AESTHETICIAN, 12-FLIGHT ATTENDANT, 13- FACTORY WORKER, 14-OTHER [SPECIFIY], 99-PREFER NOT TO ANSWER}	Have you been working in any of the following occupations or worksites in the past year [SELECT ALL THAT APPLY]
EXPOSURE	24.c	Other occupation specification	string	single		(specify)
EXPOSURE	25.a	Participant's COVID- 19 exposures before March 2020	numerical	single	[0, 1000]	How many times have you been in gatherings of more than 10 people since March 2020



CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
EXPOSURE	25.b	Participant's COVID- 19 exposures before March 2020 PNA	categorical	single	99-PREFER NOT TO ANSWER	How many times have you been in gatherings of more than 10 people since March 2020
EXPOSURE	25.c	Participant's COVID- 19 exposures before symptoms	numerical	single	[0, 1000]	If you think you have had COVID, how many times were you in gatherings of more than 10 people in the 6 months before your symptoms began
EXPOSURE		Participant's COVID- 19 exposures before symptoms PNA	categorical	single	99-PREFER NOT TO ANSWER	If you think you have had COVID, how many times were you in gatherings of more than 10 people in the 6 months before your symptoms began
HEALTH, HEALTH BEHAVIOURS	26	Participant's smoking status	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Do you currently smoke tobacco
HEALTH, HEALTH BEHAVIOURS	27	Frequency of smoking by participant	categorical	single	{01-LESS THAN DAILY, 02-DAILY, 00-NOT APPLICABLE}	How often do you smoke tobacco
HEALTH, HEALTH BEHAVIOURS	28	Participants current vaping status	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Do you currently use e-cigarettes (vape)
HEALTH, HEALTH BEHAVIOURS	29	Frequency of vaping by participant	categorical	single	{01-LESS THAN DAILY, 02-DAILY, 00-NOT APPLICABLE}	How often do you use e-cigarettes (vape)
HEALTH, HEALTH BEHAVIOURS	30	Participant's Comorbidities				Have you been diagnosed by a physician with any of the following chronic medical conditions [SELECT ALL THAT APPLY]
HEALTH, HEALTH BEHAVIOURS	30.a	Participant's Comorbidities: HYPERTENSION	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Hypertension
HEALTH, HEALTH BEHAVIOURS	30.b	Participant's Comorbidities: DIABETES	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Diabetes
HEALTH, HEALTH BEHAVIOURS	30.c	Participant's Comorbidities: ASTHMA	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Asthma
HEALTH, HEALTH BEHAVIOURS	30.d	Participant's Comorbidities: CHRONIC LUNG DISEASE	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic lung disease
HEALTH, HEALTH BEHAVIOURS	30.e	Participant's Comorbidities: CHRONIC HEART DISEASE HYPERTENSION	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic heart disease
HEALTH, HEALTH BEHAVIOURS	30.f	Participant's Comorbidities: CHRONIC KIDNEY DISEASE	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic kidney disease



COVID-19 IMMUNITY TASK FORCE GROUPE DE TRAVAIL SUR L'IMMUNITÉ FACE À LA COVID-19

CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
HEALTH, HEALTH BEHAVIOURS	30.g	Participant's Comorbidities: LIVER DISEASE	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Liver disease
HEALTH, HEALTH BEHAVIOURS	30.h	Participant's Comorbidities: CANCER	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Cancer
HEALTH, HEALTH BEHAVIOURS	30.i	Participant's Comorbidities: CHRONIC BLOOD DISORDER	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic blood disorder
HEALTH, HEALTH BEHAVIOURS	30.j	Participant's Comorbidities: IMMUNE SUPPRESSED	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic kidney disease
HEALTH, HEALTH BEHAVIOURS	30.k	Participant's Comorbidities: CHRONIC NEUROLOGICAL DISORDER	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Chronic neurological disorder
HEALTH, HEALTH BEHAVIOURS	31.a	Participant's weight	numerical	single	[1, 300]	What is your current weight
HEALTH, HEALTH BEHAVIOURS	31.b	Participant's weight units	categorical	single	{01-KG, 02-LBS}	(circle units)
HEALTH, HEALTH BEHAVIOURS	31.c	Participant's weight PNA	categorical	single	99-PREFER NOT TO ANSWER	What is your current weight
HEALTH, HEALTH BEHAVIOURS	32.a	Participant's height (m)	numerical	single	[0.5, 2.5]	What is your current height [in metres]
HEALTH, HEALTH BEHAVIOURS	32.b	Participant's height (feet)	numerical	single	[2, 8]	What is your current height [in feet and inches]
HEALTH, HEALTH BEHAVIOURS	32.c	Participant's height (inches)	numerical	single	[0, 11]	What is your current height [in feet and inches]
HEALTH, HEALTH BEHAVIOURS	32.d	Participant's height PNA	categorical	single	99-PREFER NOT TO ANSWER	What is your current height
HEALTH, HEALTH BEHAVIOURS	39	Participant's access to primary care provider or physician	categorical	single	{00-NO, 01-YES, 98-DON'T KNOW, 99-PREFER NOT TO ANSWER}	Do you have a family physician, primary care provider
HEALTH, HEALTH BEHAVIOURS	34.a	Participant's flu shot	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Do you usually get a flu shot
HEALTH, HEALTH BEHAVIOURS	35	Participant's COVID- 19 Protective Behaviours				How often have done the following since March 2020
HEALTH, HEALTH BEHAVIOURS	35.a	Participant's COVID- 19 Protective Behaviours: use of mask	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 99-PREFER NOT TO ANSWER}	Worn a mask in public places



CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
HEALTH, HEALTH BEHAVIOURS	35.b	Participant's COVID- 19 Protective Behaviours: physical distancing	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 99-PREFER NOT TO ANSWER}	Practiced physical distancing in public places
HEALTH, HEALTH BEHAVIOURS	35.c	Participant's COVID- 19 Protective Behaviours: crowd avoidance	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 99-PREFER NOT TO ANSWER}	Avoided crowded places, gatherings
HEALTH, HEALTH BEHAVIOURS	35.d	Participant's COVID- 19 Protective Behaviours: greeting avoidance	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 99-PREFER NOT TO ANSWER}	Avoided common greetings (such as handshake or hug)
HEALTH, HEALTH BEHAVIOURS	35.e	Participant's COVID- 19 Protective Behaviours: contact limit with vulnerable population	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Limited contact with people at higher risk (e.g., an elderly relative)
HEALTH, HEALTH BEHAVIOURS	35.f	Participant's COVID- 19 Protective Behaviours: self isolation due to symptoms	categorical	single	{01-YES, 00-NO, 97-NOT APPLICABLE}	Self-isolated because you thought you were infected with COVID-19
HEALTH, HEALTH BEHAVIOURS	35.g	Participant's COVID- 19 Protective Behaviours: preventative self quarantine	categorical	single	{01-YES, 00-NO, 97-NOT APPLICABLE}	Self-quarantined because you may have been exposed to COVID-19, but did not show symptoms
HEALTH, HEALTH BEHAVIOURS	36	Participant's COVID- 19 Protective Behaviours before having COVID				If you think you have had COVID, how often have you done the following in the 6 months before your symptoms began?
HEALTH, HEALTH BEHAVIOURS	36.a	Participant's COVID- 19 Protective Behaviours before having COVID: use of mask	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Worn a mask in public places
HEALTH, HEALTH BEHAVIOURS	36.b	Participant's COVID- 19 Protective Behaviours before having COVID: physical distancing	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Practiced physical distancing in public places



CITF Domain	Number	Label	Туре	Cardinality	Value constraints	Question
HEALTH, HEALTH BEHAVIOURS	36.c	Participant's COVID- 19 Protective Behaviours before having COVID: crowd avoidance	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Avoided crowded places, gatherings
HEALTH, HEALTH BEHAVIOURS	36.d	Participant's COVID- 19 Protective Behaviours before having COVID: greeting avoidance	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Avoided common greetings
HEALTH, HEALTH BEHAVIOURS	36.e	Participant's COVID- 19 Protective Behaviours before having COVID: contact limit with vulnerable population	categorical	single	{00-NEVER, 02-RARELY, 03-OCCASSIONALLY, 04-OFTEN, 05- ALWAYS, 97-NOT APPLICABLE, 99-PREFER NOT TO ANSWER}	Limited contact with people at higher risk (e.g., an elderly relative)
HEALTH, HEALTH BEHAVIOURS	36.f	Participant's COVID- 19 Protective Behaviours before having COVID: self isolation due to symptoms	categorical	single	{01-YES, 00-NO, 97-NOT APPLICABLE}	Self-isolated because you thought you were infected with COVID-19
HEALTH, HEALTH BEHAVIOURS	36.g	Participant's COVID- 19 Protective Behaviours before having COVID: preventative self quarantine	categorical	single	{01-YES, 00-NO, 97-NOT APPLICABLE}	Self-quarantined because you may have been exposed to COVID-19, but did not show symptoms
VACCINE	40	Participant's COVID- 19 Vaccine Exposure	categorical	single	{00-NO, 01-YES, 99-PREFER NOT TO ANSWER}	Have you been vaccinated against COVID-19?
VACCINE	41	Participant's COVID- 19 Vaccine Exposure: dosage	categorical	single	{00-NOT APPLICABLE, 01-1, 02-2, 03-MORE THAN TWO}	How many doses of the COVID-19 vaccine have you received so far?
VACCINE	42	Participant's COVID- 19 Vaccine Exposure: date of first dose	date	single	"YYYY-MM-DD"	When did you receive the first dose of the COVID-19 vaccine?
VACCINE	43	Participant's COVID- 19 Vaccine Exposure: date of second dose	date	single	"YYYY-MM-DD"	When did you receive the second dose of the COVID-19 vaccine?
VACCINE	44	Participant's COVID- 19 Vaccine Exposure: vaccine type	categorical	single	{01-Pfizer and BioNTech mRNA vaccine, 02-Moderna mRNA vaccine, 03-AstraZeneca Oxford Vaccine, 04-Other [Specify the vaccine], 98-Don't Know, 99-PREFER NOT TO ANSWER}	Which vaccine did you receive?
VACCINE	44.a	Other vaccine specification	string	single		(specify vaccine)

## Appendix 3

CITF Data Governance Framework

[TO BE INCLUDED BY CITF ONCE AVAILABLE]